Department of Public Health Sciences, University of California Davis, Davis, California.
Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Cancer Epidemiol Biomarkers Prev. 2022 Aug 2;31(8):1602-1609. doi: 10.1158/1055-9965.EPI-22-0069.
BACKGROUND: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/Black or Non-Hispanic White women. An Indigenous American breast cancer-protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. METHODS: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. RESULTS: We replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.47-0.59], as well as the lower odds of developing hormone receptor negative (HR-) versus HR+ disease (OR, 0.77; 95% CI, 0.61-0.97). Models, including HER2, showed further heterogeneity with reduced odds for HR+HER2+ (OR, 0.68; 95% CI, 0.51-0.92), HR-HER2+ (OR, 0.63; 95% CI, 0.44-0.90) and HR-HER2- (OR, 0.77; 95% CI, 0.56-1.05) compared with HR+HER2-. Inclusion of other risk-associated variants did not change these observations. CONCLUSIONS: The rs140068132 polymorphism is associated with decreased risk of breast cancer in Peruvians and is more protective against HR- and HER2+ diseases independently of other breast cancer-associated variants in the 6q25 region. IMPACT: These results could inform functional analyses to understand the mechanism by which rs140068132-G reduces risk of breast cancer development in a subtype-specific manner. They also illustrate the importance of including diverse individuals in genetic studies.
背景:与非西班牙裔白种人或非裔美国/黑种人相比,西班牙裔/拉丁裔(H/L)美国人的乳腺癌发病率较低。一种已报道的与乳腺癌相关的种系变体(rs140068132)位于雌激素受体 1 基因附近。本研究检测了 H/L 人群中高印第安人血统个体中位于 6q25 区域的 rs140068132 及其他多态性与特定乳腺癌亚型风险的相关性。
方法:对 5094 名秘鲁女性进行了基因分型,其中 1755 名患有乳腺癌,3337 名未患有乳腺癌。采用逻辑回归模型和条件分析检测保护型变体与整体及特定亚型乳腺癌风险之间的相关性,包括该区域内的其他与风险相关的多态性。
结果:我们复制了 rs140068132 与乳腺癌风险之间的关联,该关联在总体上表现为[比值比(OR),0.53;95%置信区间(CI),0.47-0.59],以及与激素受体阴性(HR-)相比,发生 HR+疾病的几率更低(OR,0.77;95%CI,0.61-0.97)。包含 HER2 的模型显示出更大的异质性,HR+HER2+(OR,0.68;95%CI,0.51-0.92)、HR-HER2+(OR,0.63;95%CI,0.44-0.90)和 HR-HER2-(OR,0.77;95%CI,0.56-1.05)的 HR+HER2-风险降低。包含其他与乳腺癌相关的变异并不会改变这些观察结果。
结论:rs140068132 多态性与秘鲁人乳腺癌风险降低有关,并且独立于 6q25 区域内的其他与乳腺癌相关的变异,对 HR-和 HER2+疾病的保护作用更强。
影响:这些结果可以为理解 rs140068132-G 以特定于乳腺癌亚型的方式降低乳腺癌发病风险的机制提供功能分析依据。它们还说明了在遗传研究中纳入不同人群的重要性。
Cancer Epidemiol Biomarkers Prev. 2022-8-2
J Natl Cancer Inst. 2012-7-5
Cancer Epidemiol Biomarkers Prev. 2012-11-7
Cancer Epidemiol Biomarkers Prev. 2015-11
Breast Cancer Res. 2019-1-14
Breast Cancer Res Treat. 2017-8-30
Cancer Epidemiol Biomarkers Prev. 2025-2-6
Front Oncol. 2023-2-16
CA Cancer J Clin. 2021-1
Br J Cancer. 2021-1
Breast Cancer Res. 2019-1-14
BMC Genomics. 2018-12-11